Skip to content
Search

Latest Stories

Britain approves Merck's Covid-19 pill in world first

BRITAIN on Thursday (4) became the first country in the world to approve a potentially game-changing Covid-19 antiviral pill jointly developed by US-based Merck & Co Inc and Ridgeback Biotherapeutics, in a boost to the fight against the pandemic.

Britain's Medicines and Healthcare products Regulatory Agency (MHRA) recommended the drug, molnupiravir, for use in people with mild to moderate Covid-19 and at least one risk factor for developing severe illness, such as obesity, older age diabetes, and heart disease.


It will be administered as soon as possible following a positive Covid-19 test and within five days of the onset of symptoms, the regulator said, citing clinical data.

The green light is the first for an oral antiviral treatment for Covid-19 and the first for a Covid-19 drug that will be administered widely in the community. US advisers will meet on Nov. 30 to review the drug's safety and efficacy data and vote on whether molnupiravir should be authorised.

The pill, which will be branded as Lagevrio in Britain, is designed to introduce errors into the genetic code of the coronavirus that causes Covid-19 and is taken twice a day for five days.

Meanwhile, last month Dr Yusuf Hamied had confirmed Eastern Eye that Cipla, his pharma company in India, has been given a licence to manufacture the new anti-Covid pill called Molnupiravir.

Drugs in the same class as molnupiravir have been linked to birth defects in animal studies. Merck, known as MSD outside of the United States and Canada, has said animal testing shows that molnupiravir is safe, but the data have not yet been made public.

Treatments to tackle the pandemic, which has killed more than 5.2 million people worldwide, have so far focused mainly on vaccines. Other options, including Gilead's infused antiviral remdesivir and generic steroid dexamethasone, are generally only given after a patient has been hospitalised.

Merck's Molnupiravir has been closely watched since data last month showed it could halve the chances of dying or being hospitalised for those most at risk of developing severe Covid-19 when given early in the illness.

Professor Stephen Powis, national medical director for the National Health Service (NHS) in England, said the drug would be administered to patients at higher risk of complications as Britain heads into one of the most challenging winters ever.

A wider rollout will follow if it is clinically and cost effective in reducing hospitalisations and death, he added.

"We are now working across government and the NHS to urgently get this treatment to patients initially through a national study so we can collect more data on how antivirals work in a mostly vaccinated population," UK vaccines minister Maggie Throup told parliament.

PRESSURES

The speedy approval in Britain, which was also the first Western country to approve a Covid-19 vaccine, comes as it struggles to tame soaring infections.

Britain has about 40,000 daily cases of Covid-19, according to the latest seven-day average. That is second only to the roughly 74,000 a day in the United States, which has five times more people, and has fuelled criticism of the government's decision to abandon most pandemic-related restrictions

Data released on Wednesday night showed Covid-19 prevalence in England hit its highest level on record last month, led by a high number of cases in children and a surge in the south-west of the country.

Pressure is growing on the government to implement its "Plan B" aimed at protecting the NHS from unsustainable demands, involving mask mandates, vaccine passes and work-from-home orders.

Many other big economies, including Germany, France and Israel, have either retained some basic Covid-19 measures like mask mandates or reintroduced them in response to rising cases.

The UK government has said its focus remains on administering vaccine boosters and inoculating 12- to 15-year-olds.

"With no compromises on quality, safety and effectiveness, the public can trust that the MHRA has conducted a robust and thorough assessment of the data (on molnupiravir)," MHRA chief June Raine said in a statement.

Last month, Britain agreed a deal with Merck to secure 480,000 courses of molnupiravir.

Professor Penny Ward, an independent pharmaceutical physician, welcomed the approval, but said the NHS needed to outline its plans for rollout and cautioned that supplies were likely to be tight given the strong global demand.

"Comments made by Mr Javid today suggest that it may be made available via a clinical trial, presumably to investigate its effectiveness in vaccinated patients with breakthrough infections, as the original study incorporated unvaccinated adults," she said.

If given to everyone becoming unwell, the nearly half a million courses would not last very long given the more than 40,000 current daily case rate, she said.

TREATMENT RACE

In a separate statement, Merck said it expected to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.

The US-based drugmaker's shares rose 2.1% to close at $90.54 on Thursday.

Pfizer and Roche are also racing to develop easy-to-administer antiviral pills for Covid-19.

Both Merck and Pfizer are studying their drugs in late-stage trials for preventing coronavirus infection.

Viral sequencing done so far has shown molnupiravir is effective against all variants of the coronavirus, Merck has said, including the more-infectious Delta, which is responsible for the worldwide surge in hospitalisations and deaths recently.

While it is not yet clear when Merck will deliver doses to Britain, the company has said it is committed to providing timely access to its drug globally with plans for tiered pricing aligned with a country's ability to pay.

Merck has licensed the drug to generic drugmakers for supply to low-income countries.

Antibody cocktails like those from Regeneron and Eli Lilly have also been approved for non-hospitalised Covid-19 patients, but have to be given intravenously.

(With Reuters inputs)

More For You

Andrew Tate Sued by Ex-Girlfriend Brianna Stern Over Sexual Assault Allegations

Tate’s attorney, Joseph McBride, has dismissed the lawsuit

Getty

Andrew Tate faces sexual assault lawsuit from ex-girlfriend Brianna Stern

Social media personality Andrew Tate is facing a new lawsuit from his ex-girlfriend, Brianna Stern, who has accused him of sexual assault, battery, and gender violence. The lawsuit, filed in Los Angeles, details allegations of abuse and an incident that allegedly took place at The Beverly Hills Hotel on 11 March 2025.

Allegations in the lawsuit

According to the legal complaint, Stern claims that Tate initially appeared as a "dream come true" but later became emotionally and physically abusive. The lawsuit describes a violent encounter at the hotel, where she alleges Tate physically assaulted and threatened her.

Keep ReadingShow less
Voices of Faith 2025: A journey through spirituality and wisdom

Soumik Datta (R) and Gurdain Singh Rayatt

Voices of Faith 2025: A journey through spirituality and wisdom

Mahesh Liloriya

The inaugural edition of Voices of Faith commenced on Friday at the iconic Barbican Centre, Silk Street, London, marking the beginning of an extraordinary three-day festival exploring theological philosophies, interfaith dialogues, and the deeper essence of spirituality through conversations, music, and healing vibes.

Organised by Teamwork Arts, the creators of the Jaipur Literature Festival (JLF) and JLF London, Voices of Faith is presented by the Kamini and Vindi Banga Family Trust, with the support of Tech Mahindra. Eastern Eye and Garavi Gujarat serve as the official media partners of this landmark event. This unique festival seeks to offer insights into navigating the complexities of modern life through the timeless wisdom enshrined in global religious traditions. It focuses on the universal ideals of compassion and interconnectedness that underpin the world’s faiths, fostering dialogue that transcends barriers and deepens mutual understanding.

Keep ReadingShow less
Court reopens Asian child sex offender's deportation case

Home Office successfully challenged a ruling that allowed him to remain in Britain (Photo for representation: iStock)

Court reopens Asian child sex offender's deportation case

A PAKISTANI man convicted of sexually assaulting a child under 13 will face a fresh deportation hearing after the Home Office successfully challenged a ruling that allowed him to remain in Britain, reported The Times.

The offender, who cannot be named for legal reasons, had initially won his case to stay in the UK after claiming he would face "inhuman or degrading treatment" if sent back to Pakistan due to his alcoholism.

Keep ReadingShow less
India launches Operation Brahma to aid quake-hit Myanmar

Rescue teams work to save residents trapped under the rubble of the destroyed Sky Villa Condominium development in Mandalay on March 29, 2025. (Photo by SAI AUNG MAIN/AFP via Getty Images)

India launches Operation Brahma to aid quake-hit Myanmar

INDIA has swiftly responded to the devastating earthquake in Myanmar by launching Operation Brahma, sending emergency relief and rescue teams to the disaster-stricken nation.

A C-130J military transport aircraft of the Indian Air Force landed in Yangon on Saturday (29), carrying 15 tonnes of relief supplies including hygiene kits, blankets and food parcels. The aid mission comes after a powerful 7.7-magnitude earthquake struck Myanmar on Friday (28), killing more than 1,000 people and injuring nearly 2,400 others.

Keep ReadingShow less
Britain’s happiness crisis: UK hits record low in global wellbeing rankings

Pakistan stands at 109th place out of 147 countries

Britain’s happiness crisis: UK hits record low in global wellbeing rankings

THE UK has experienced a significant blow to its national morale, plummeting to 23rd place in the World Happiness Report for 2025 – its lowest ranking ever – despite being the world’s sixth richest nation.

Released to mark the UN’s International Day of Happiness last Thursday (20), the report provided a nuanced exploration of national contentment that extends far beyond economic measurements.

Keep ReadingShow less